Table 2.
AIC and BIC values for modeling progression-free survival.
| Progression-Free Survival | Atezolizumab + Bevacizumab | Sorafenib | ||
|---|---|---|---|---|
|
|
|
|
||
| Model | AIC | BIC | AIC | BIC |
| Weibull (PH) | 1324.73 | 1339.99 | 614.65 | 623.96 |
| Weibull (AFT) | 1324.39 | 1339.66 | 614.65 | 623.97 |
| Log-normal | 1303.07 | 1318.34 | 602.72 | 612.04 |
| Log-logistic | 1312.27 | 1327.54 | 607.17 | 616.49 |
| Gen. Gamma | 1298.79 | 1317.87 | 604.54 | 616.97 |
| Gen. F | 1304.04 | 1326.94 | 607.36 | 622.89 |
| Gamma | 1321.63 | 1336.89 | 610.63 | 619.95 |
| Exponential | 1328.63 | 1340.08 | 627.42 | 633.63 |
AIC: Akaike information criterion; BIC: Bayesian information criterion.